Bloomsbury Publishing Sees Profit Surge Ahead with Sarah J. Maas Book Announcements

What “market consensus” means here

Market consensus is the company’s view of the average analyst forecast. Bloomsbury has put the relevant figures on the record:

Metric	Consensus (pre-announcement)	Company comment
FY 2025/26 profit before taxation and highlighted items	£44.3m	In line
FY 2026/27 profit before taxation and highlighted items	£44.5m	Now expected to be materially ahead
ACOTAR new novel release dates	27 Oct 2026 and 12 Jan 2027	Both fall in FY 2026/27

Commercial read-through: what could drive the uplift

We do not have unit forecasts or print-run details – not disclosed – but we do have powerful signals. Maas’s sales momentum, the compressed release window, and the dual-peak retail timing together improve the odds of outsized front-list performance and a halo effect on the backlist. Bloomsbury also highlights the Academic division as strong in FY26, offering ballast if trade publishing gets bumpy.

The bigger strategic point is that Bloomsbury’s diversified portfolio has carried FY26 to plan, while a single author’s event releases can tilt FY27 meaningfully higher. That blend – a steady academic engine with hit-driven trade upside – is what management means by a “portfolio of portfolios”.

Positives, watch-outs and what comes next

Reasons to be cheerful

• Two ACOTAR novels within 11 weeks is a rare and potent sales catalyst.
• Both titles land inside FY27, neatly aligning creative output with financial guidance.
• FY26 is in line, suggesting operational discipline and helpful diversification.
• Academic division flagged as strong – an important counterweight to trade cyclicality.
• Author momentum is proven: highest selling author in the US in 2024 and UK No.1 Fantasy in 2025.

Key uncertainties to keep in mind

• Bloomsbury has not quantified how far “materially ahead” goes, so the size of the beat is unknown.
• Execution risks always exist around major releases – supply chain, printing, and timing – though none are flagged.
• Concentration risk is implicit when a single franchise drives guidance upgrades, even within a diversified group.

Milestones and catalysts to watch

• Preliminary Results on 20 May 2026 – expect more colour on trading and possibly FY27 phasing.
• Pre-order traction and retailer placement in the run-up to October 2026 – not disclosed today, but likely to be important.
• Any updates on marketing plans and international roll-out – not disclosed in this RNS.

My take: a textbook set-up for FY27 with credible support in FY26

This is a tidy update. FY26 lands where the market expects at £44.3m profit before tax and highlighted items, underpinned by the Academic division. The bigger news is the ACOTAR double-drop inside FY27, which now takes the company “materially ahead” of the pre-RNS £44.5m consensus.

Could this be conservative? Possibly. The timing straddles both Christmas and the new-year retail window, and Maas’s track record is exceptional. But without disclosed numbers, it is sensible to take the company’s language at face value and wait for May’s prelims to sharpen the range.

Net-net, Bloomsbury is signalling confidence built on two pillars: a resilient base and genuine hit potential. If execution stays tight, FY27 could be a standout year.

Essential details at a glance

• FY 2025/26 outcome: in line with market consensus of £44.3m profit before tax and highlighted items.
• FY 2026/27 outlook: now expected to be materially ahead of consensus of £44.5m.
• Sarah J. Maas ACOTAR releases: 27 October 2026 and 12 January 2027.
• Academic division: strong performance noted in FY26.
• Preliminary Results: scheduled for 20 May 2026.
• Inside information: this announcement is designated as such under MAR.